Salute e Benessere
Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
Investigating improvements in blood sugar and cardiovascular risk factors
In an OASIS 4 post hoc analysis, investigators explored improvements in glycemic parameters and cardiovascular risk factors for people with obesity or overweight treated with once-daily oral semaglutide 25 mg.
Examining the efficacy of semaglutide across formulations (pill and injectable) in women's health
Additional post hoc analyses from OASIS 4 and STEP phase 3a trials examined the efficacy of semaglutide in reducing body weight in women in pre- and post-menopausal stages, and another assessed improved physical function based on patient-reported outcomes data.
Comparing efficacy of semaglutide in a pill with injectable semaglutide (Wegovy )
Indirect trial comparison of OASIS 4 with STEP 1 comparing efficacy between once-daily oral semaglutide 25 mg with injectable once-weekly semaglutide 2.4 mg.
Additional phase 3 data from REDEFINE 1 included analyses exploring the cardiovascular risk reduction potential of investigational CagriSema and examining the percentage of people treated with CagriSema who achieved clinically relevant treatment targets for obesity management.
Additional analysis of data from STEP UP with semaglutide 2.4 mg and 7.2 mg assessed risk of obesity-related complications using clinically relevant treatment targets.
Tradename of 'Wegovy pill' submitted to the FDA and is pending approval.
Oral semaglutide 25 mg (Wegovy in a pill ), semaglutide 7.2 mg, and CagriSema are not approved in the US or in Europe .
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.
Injectable semaglutide 2.4 mg is marketed under the brand name Wegovy . In the EU, Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m or greater (obesity) or adults with a BMI of 27 kg/m or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95 percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis.
In the US, Wegovy (semaglutide) injection 2.4 mg is currently approved along with a reduced calorie diet and increased physical activity, for adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off and to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight. It is important to note that semaglutide injection 2.4 mg contains a Boxed Warning for possible thyroid tumors, including cancer and should not be used in those with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
© 2025 Novo Nordisk All rights reserved. US25SEMO03076 October 2025
Logo - https://mma.prnewswire.com/media/466582/Novo_Nordisk_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/novo-nordisk-to-present-new-data-in-oral-semaglutide-25-mg-wegovy-in-a-pill-and-obesity-pipeline-at-obesityweek-2025-302588914.html